Sublingual Edaravone Dexborneol Effective for Acute Ischemic Stroke
A double-blind, placebo-controlled, multicenter, parallel-group, phase 3 randomized clinical trial in China revealed that sublingual edaravone dexborneol improved functional outcome at 90 days compared to placebo in patients with acute ischemic stroke (AIS). Within 48 hours of diagnosis, 914 AIS patients (median age, 64.0 [56.0-70.0] years; male 66.5%) were randomly […]